Torrent Pharmaceuticals Limited CC-Feb26.pdf · 2026-02-13
Yes, hi. Thank you and good evening. Just a clarification on the synergy number, INR 400-INR 450 crores in the next 2 -3 years. So, JB has this Novartis' Ophthal portfolio which is currently in-licensing. There is an opportunity for growing gross margins on that portfolio by FY '28. So, the INR 400-INR 450 crores number is inclusive of that gross margin synergies on the Ophthal portfolio of Novartis?
Perfect. Thank you. Secondly, on the Brazil ex of Semaglutide, I think one of your peers reported quarterly numbers where they had a new launch and high growth with DAPA. So, any guidance on the number of new product launches in Brazil ex of Sema and how that growth trajectory can look like for the next 2-3 years, please?